Home LiteratureArticle Details
PMID: 21593776 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Mechanisms of resistance to RAF inhibitors in melanoma.

The Journal of investigative dermatology ·Vol. 131 ·No. 9 ·2011-09-00 ·Pages 1817-20

Aplin AE, Kaplan FM, Shao Y

Abstract

The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.

MeSH Terms
Drug Resistance, Neoplasm/physiology Humans Indoles/therapeutic use Melanoma/drug therapy Protein Kinase Inhibitors/therapeutic use Skin Neoplasms/drug therapy Sulfonamides/therapeutic use Vemurafenib raf Kinases/antagonists & inhibitors
Chemicals
Indoles Protein Kinase Inhibitors Sulfonamides Vemurafenib raf Kinases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Aplin Andrew E
Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. Andrew.Aplin@KimmelCancerCenter.Org
Kaplan Fred M
Shao Yongping
References (21)
21 references, click to expand
  1. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Cancer Res. 2008 Jun 15;68(12):4853-61 PMID: 18559533
  2. Inhibition of mutated, activated BRAF in metastatic melanoma.
    N Engl J Med. 2010 Aug 26;363(9):809-19 PMID: 20818844
  3. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
    Mol Cancer Ther. 2008 Sep;7(9):2876-83 PMID: 18790768
  4. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
    Cell. 2010 Apr 2;141(1):69-80 PMID: 20371346
  5. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Oncogene. 2005 May 12;24(21):3459-71 PMID: 15735667
  6. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
    Sci Transl Med. 2010 Jun 9;2(35):35ra41 PMID: 20538618
  7. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
    Ann Intern Med. 2010 Nov 2;153(9):587-91 PMID: 21041578
  8. Melanoma--an unlikely poster child for personalized cancer therapy.
    N Engl J Med. 2010 Aug 26;363(9):876-8 PMID: 20818849
  9. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
    Nature. 2010 Sep 30;467(7315):596-9 PMID: 20823850
  10. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Neoplasia. 2010 Aug;12(8):637-49 PMID: 20689758
  11. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
    Cancer Cell. 2010 Dec 14;18(6):683-95 PMID: 21156289
  12. New insight into BRAF mutations in cancer.
    Curr Opin Genet Dev. 2007 Feb;17(1):31-9 PMID: 17208430
  13. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nature. 2010 Dec 16;468(7326):973-7 PMID: 21107323
  14. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
    J Invest Dermatol. 2010 Nov;130(11):2669-71 PMID: 20574441
  15. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
    Cancer Res. 2010 Aug 15;70(16):6670-81 PMID: 20647317
  16. Loss of Rb overrides the requirement for ERK activity for cell proliferation.
    J Cell Sci. 2002 Dec 1;115(Pt 23):4607-16 PMID: 12415005
  17. Mutations of the BRAF gene in human cancer.
    Nature. 2002 Jun 27;417(6892):949-54 PMID: 12068308
  18. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Nature. 2010 Mar 18;464(7287):427-30 PMID: 20179705
  19. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Nature. 2010 Dec 16;468(7326):968-72 PMID: 21107320
  20. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
    Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6 PMID: 19915144
  21. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.
    Br J Cancer. 2010 Jun 8;102(12):1724-30 PMID: 20531415
Article Info
Journal
The Journal of investigative dermatology
Abbr.
J Invest Dermatol
ISSN
1523-1747
DOI
10.1038/jid.2011.147
Email
andrew.aplin@kimmelcancercenter.org
Published
2011-09-00
Epub
2011-00-19
Pages
1817-20
Language
English
Region
United States
NLM ID
0426720
PMCID
PMC3156870
Subset
IM
Grants
NIGMS NIH HHS · R01 GM067893 · United States
NCI NIH HHS · R01 CA125103-05 · United States
NIGMS NIH HHS · GM067893 · United States
NIGMS NIH HHS · R01 GM067893-06S1 · United States
NIGMS NIH HHS · R01 GM067893-08 · United States
NCI NIH HHS · R01 CA125103-04 · United States
NCI NIH HHS · R01 CA125103-03 · United States
NCI NIH HHS · R01 CA125103 · United States
NIGMS NIH HHS · R01 GM067893-07A1 · United States
NIGMS NIH HHS · R01 GM067893-09 · United States
NCI NIH HHS · CA125103 · United States
External Links
PubMed source DOI: 10.1038/jid.2011.147 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2